Driven by the company's proprietary blocker displacement amplification technology, the test can detect and quantitate over 6,500 mutations and indels in 61 clinically relevant genes, according to the company. The high sensitivity possible with the product is suitable for detection of minimal residual disease in acute myeloid leukemia and other diseases, NuProbe said in a statement.